SKYE · Skye Bioscience, Inc. · Debt
$1.54
-0.08 (-4.94%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.82M
Shares
4.43M
Volume · Oct 23
12.77K
Avg daily vol (44 sessions)
63.45K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 35,696 | 10-Q filed 2026-08-14 |
| Current portion of loans payable | 2026-06-30 | USD 143,050 | 10-Q filed 2026-08-14 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 0 | 10-Q filed 2026-08-14 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.